- Home
- SCYX vs DTST Comparison
SCYX vs DTST Comparison
Compare SCYX & DTST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- DTST
- Stock Information
- Founded
- SCYX 1999
- DTST 2001
- Country
- SCYX United States
- DTST United States
- Employees
- SCYX N/A
- DTST N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- DTST EDP Services
- Sector
- SCYX Health Care
- DTST Technology
- Exchange
- SCYX Nasdaq
- DTST Nasdaq
- Market Cap
- SCYX 28.5M
- DTST 28.2M
- IPO Year
- SCYX 2014
- DTST N/A
- Fundamental
- Price
- SCYX $0.82
- DTST $3.44
- Analyst Decision
- SCYX
- DTST
- Analyst Count
- SCYX 0
- DTST 0
- Target Price
- SCYX N/A
- DTST N/A
- AVG Volume (30 Days)
- SCYX 176.2K
- DTST 30.5K
- Earning Date
- SCYX 08-07-2025
- DTST 08-13-2025
- Dividend Yield
- SCYX N/A
- DTST N/A
- EPS Growth
- SCYX N/A
- DTST N/A
- EPS
- SCYX N/A
- DTST 0.02
- Revenue
- SCYX $2,630,000.00
- DTST $25,219,312.00
- Revenue This Year
- SCYX $463.61
- DTST $12.57
- Revenue Next Year
- SCYX $310.80
- DTST $9.29
- P/E Ratio
- SCYX N/A
- DTST $147.31
- Revenue Growth
- SCYX N/A
- DTST N/A
- 52 Week Low
- SCYX $0.66
- DTST $2.93
- 52 Week High
- SCYX $2.29
- DTST $6.53
- Technical
- Relative Strength Index (RSI)
- SCYX 57.87
- DTST 49.28
- Support Level
- SCYX $0.67
- DTST $3.33
- Resistance Level
- SCYX $0.75
- DTST $3.56
- Average True Range (ATR)
- SCYX 0.04
- DTST 0.13
- MACD
- SCYX 0.01
- DTST 0.02
- Stochastic Oscillator
- SCYX 93.53
- DTST 70.00
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.